Pembrolizumab/axitinib too costly in advanced renal cell carcinoma
Source: PharmacoEconomics and Outcomes News - Category: Drugs & Pharmacology Source Type: news
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Kidney Cancer | Renal Cell Carcinoma